BD (Becton, Dickinson and Company), a leading global medical technology company, will demonstrate an enhanced technology platform designed with the ability to synchronize BD medication management technologies, including the company’s leading Pyxis™ and Alaris™ systems, at this year’s American Society of Health-System Pharmacists (ASHP) 2016 Midyear Meeting being held in Las Vegas from Dec. 4-8.
While national data show that approximately 68 percent of medication errors occur during the administration phase, errors can happen during any step of the medication management processi. During last year’s ASHP Midyear Meeting, BD revealed how its strong portfolio of solutions can help improve the safety and cost of healthcare during each step of the process. Since then, BD is continuing its focus on creating a new enterprise medication management platform that will harmonize its advanced technologies to close the communication gaps between devices and help optimize the entire medication management process. This unique approach is coupled with new services, backed by clinical experts that will support a hospital or health system to define, execute and measure its medication management processes and continuously improve workflows and optimize processes.
“BD is a leader in medication management technologies because of our continued commitment to innovation and deep understanding of the customer challenges with medications,” said Ranjeet Banerjee, worldwide president of Medication Management Solutions for BD. “We know it’s not enough to simply have the right technologies in place if they aren’t connected to other parts of the process. BD’s innovation roadmap includes device hardware, interoperability software, data analytics applications and services creating an interconnected system that is designed to help improve outcomes across the continuum of care.”
During ASHP, BD will showcase the medication management processes and illustrate how medication safety and efficiency can be enhanced across the care continuum by combining three key elements to improve customer outcomes:
Medication Management Platform Innovation: From medication reconciliation upon admission, dispensing in the pharmacy and administration at the bedside, BD will showcase leading technologies to help hospitals and health systems manage inventory, prepare IV medications and safely dispense and administer medications along with tracking technologies to know where medications are from the pharmacy to the bedside.
Advanced Data and Analytics: New BD analytics applications can provide recommendations on ways to optimize the medication management system for peak safety and efficiency, which complements EHR data and helps improve workflow and patient safety.
Customer-centric Support and Services: BD is implementing new services that will help hospitals and health systems review and understand its own medication management data and determine opportunities to improve outcomes.
For more information, or to register for any of the BD-sponsored activities at ASHP, please visit us at Booth #821.
BD (bd.com) is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has more than 40,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health.
This press release contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding potential future sales and product development. Forward looking statements may be identified by use of words such as “will”,“plan”,“believe”,“expect” or other words of similar meaning. All such statements are based upon the current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. A number of factors could cause actual results to vary materially, including, without limitation, difficulties inherent in product development, delays in product introductions and uncertainty of market acceptance of new products; competitive factors including technological advances and new products introduced by competitors; pricing and market pressures; potential cuts in governmental healthcare spending and measures to contain healthcare costs; adverse changes in regional, national or foreign economic conditions; product efficacy or safety concerns; fluctuations in costs and availability of materials and in BD's ability to maintain favorable supplier arrangements and relationships; new or changing laws and regulations impacting our business or changes in enforcement practices with respect to such laws; future healthcare reform; as well as other factors discussed in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.
I California Hospital Patient Safety Organization (2012, October). Patient Safety News. 4(9).
Contact: Monique N. Dolecki - BD Investor Relations
P: 201 847 5378 - E: monique_dolecki[.]bd.com.